1.
2.
3.
4.
5.
6.
7.
8.
9.
Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Pineros, M.; Znaor, A.; Bray, F. Estimating
the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019,
144, 1941–1953. [CrossRef] [PubMed]
Latimer, K.M.; Mott, T.F. Lung cancer: Diagnosis, treatment principles, and screening. Am. Fam. Physician
2015, 91, 250–256. [PubMed]
Shaurova, T.; Zhang, L.; Goodrich, D.W.; Hershberger, P.A. Understanding Lineage Plasticity as a Path
to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer. Front. Genet. 2020, 11, 281.
[CrossRef] [PubMed]
Travis, W.D.; Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.; Yatabe, Y.; Powell, C.A.; Beer, D.;
Riely, G.; Garg, K.; et al. International Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma:
Executive summary. Proc. Am. Thorac. Soc. 2011, 8, 381–385. [CrossRef]
Socinski, M.A.; Obasaju, C.; Gandara, D.; Hirsch, F.R.; Bonomi, P.; Bunn, P.; Kim, E.S.; Langer, C.J.; Natale, R.B.;
Novello, S.; et al. Clinicopathologic Features of Advanced Squamous NSCLC. J. Thorac. Oncol. 2016, 11,
1411–1422. [CrossRef]
Devarakonda, S.; Morgensztern, D.; Govindan, R. Genomic alterations in lung adenocarcinoma. Lancet Oncol.
2015, 16, e342–e351. [CrossRef]
Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.;
Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl.
J. Med. 2009, 361, 947–957. [CrossRef]
Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.;
Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European
patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre,
open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13, 239–246. [CrossRef]
Yu, H.A.; Arcila, M.E.; Rekhtman, N.; Sima, C.S.; Zakowski, M.F.; Pao, W.; Kris, M.G.; Miller, V.A.; Ladanyi, M.;
Riely, G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients
with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19, 2240–2247. [CrossRef]
Cancers 2020, 12, 3074
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
12 of 13
Travis, W.D.; Brambilla, E.; Nicholson, A.G.; Yatabe, Y.; Austin, J.H.M.; Beasley, M.B.; Chirieac, L.R.; Dacic, S.;
Duhig, E.; Flieder, D.B.; et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of
Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J. Thorac. Oncol. 2015, 10, 1243–1260.
[CrossRef]
Regales, L.; Balak, M.N.; Gong, Y.; Politi, K.; Sawai, A.; Le, C.; Koutcher, J.A.; Solit, D.B.; Rosen, N.;
Zakowski, M.F.; et al. Development of new mouse lung tumor models expressing EGFR T790M mutants
associated with clinical resistance to kinase inhibitors. PLoS ONE 2007, 2, e810. [CrossRef]
Politi, K.; Zakowski, M.F.; Fan, P.D.; Schonfeld, E.A.; Pao, W.; Varmus, H.E. Lung adenocarcinomas induced
in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to
down-regulation of the receptors. Genes Dev. 2006, 20, 1496–1510. [CrossRef] [PubMed]
Ji, H.; Li, D.; Chen, L.; Shimamura, T.; Kobayashi, S.; McNamara, K.; Mahmood, U.; Mitchell, A.; Sun, Y.;
Al-Hashem, R.; et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and
in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9, 485–495. [CrossRef]
Xu, X.; Liu, T.; Wang, Y.; Fu, J.; Yang, Q.; Wu, J.; Zhou, H. miRNA-mRNA Associated with Survival in
Endometrial Cancer. Front. Genet. 2019, 10, 743. [CrossRef] [PubMed]
Rivera-Reyes, A.; Hayer, K.E.; Bassing, C.H. Genomic Alterations of Non-Coding Regions Underlie Human
Cancer: Lessons from T-ALL. Trends Mol. Med. 2016, 22, 1035–1046. [CrossRef]
Oldridge, D.A.; Wood, A.C.; Weichert-Leahey, N.; Crimmins, I.; Sussman, R.; Winter, C.; McDaniel, L.D.;
Diamond, M.; Hart, L.S.; Zhu, S.; et al. Genetic predisposition to neuroblastoma mediated by a LMO1
super-enhancer polymorphism. Nature 2015, 528, 418–421. [CrossRef]
Liu, C.; Tian, X.; Zhang, J.; Jiang, L. Long Non-coding RNA DLEU1 Promotes Proliferation and Invasion by
Interacting With miR-381 and Enhancing HOXA13 Expression in Cervical Cancer. Front. Genet. 2018, 9, 629.
[CrossRef]
Abildgaard, C.; Do Canto, L.M.; Steffensen, K.D.; Rogatto, S.R. Long Non-coding RNAs Involved in Resistance
to Chemotherapy in Ovarian Cancer. Front. Oncol. 2019, 9, 1549. [CrossRef]
Ramirez, M.; Rajaram, S.; Steininger, R.J.; Osipchuk, D.; Roth, M.A.; Morinishi, L.S.; Evans, L.; Ji, W.;
Hsu, C.H.; Thurley, K.; et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer
persister cells. Nat. Commun. 2016, 7, 10690. [CrossRef]
Hata, A.N.; Niederst, M.J.; Archibald, H.L.; Gomez-Caraballo, M.; Siddiqui, F.M.; Mulvey, H.E.; Maruvka, Y.E.;
Ji, F.; Bhang, H.E.; Krishnamurthy Radhakrishna, V.; et al. Tumor cells can follow distinct evolutionary paths
to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 2016, 22, 262–269. [CrossRef]
[PubMed]
Ma, C.; Wei, S.; Song, Y. T790M and acquired resistance of EGFR TKI: A literature review of clinical reports.
J. Thorac. Dis. 2011, 3, 10–18.
Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Janne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.;
Tenen, D.G.; Halmos, B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl.
J. Med. 2005, 352, 786–792. [CrossRef] [PubMed]
Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired
resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR
kinase domain. PLoS Med. 2005, 2, e73. [CrossRef] [PubMed]
Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; Woo, M.S.; Greulich, H.; Wong, K.K.; Meyerson, M.; Eck, M.J.
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl.
Acad. Sci. USA 2008, 105, 2070–2075. [CrossRef]
Martin-Fernandez, M.L.; Clarke, D.T.; Roberts, S.K.; Zanetti-Domingues, L.C.; Gervasio, F.L. Structure and
Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small
Cell Lung Cancer. Cells 2019, 8, 316. [CrossRef]
Abe, K.; Hazama, M.; Katoh, H.; Yamamura, K.; Suzuki, M. Establishment of an efficient BAC transgenesis
protocol and its application to functional characterization of the mouse Brachyury locus. Exp. Anim. 2004,
53, 311–320. [CrossRef]
D’Alessandro-Gabazza, C.N.; Kobayashi, T.; Boveda-Ruiz, D.; Takagi, T.; Toda, M.; Gil-Bernabe, P.; Miyake, Y.;
Yasukawa, A.; Matsuda, Y.; Suzuki, N.; et al. Development and preclinical efficacy of novel transforming
growth factor-beta1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 46,
397–406. [CrossRef]
Cancers 2020, 12, 3074
28.
29.
13 of 13
D’Alessandro-Gabazza, C.N.; Kobayashi, T.; Yasuma, T.; Toda, M.; Kim, H.; Fujimoto, H.; Hataji, O.;
Takeshita, A.; Nishihama, K.; Okano, T.; et al. A Staphylococcus pro-apoptotic peptide induces acute
exacerbation of pulmonary fibrosis. Nat. Commun. 2020, 11, 1539. [CrossRef] [PubMed]
Fujiwara, K.; Kobayashi, T.; Fujimoto, H.; Nakahara, H.; D’Alessandro-Gabazza, C.N.; Hinneh, J.A.;
Takahashi, Y.; Yasuma, T.; Nishihama, K.; Toda, M.; et al. Inhibition of Cell Apoptosis and Amelioration of
Pulmonary Fibrosis by Thrombomodulin. Am. J. Pathol. 2017, 187, 2312–2322. [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
...
論文の公開元へ
